Respiratory Syncytial Virus (RSV) - Market Insight, Epidemiology And Market Forecast - 2032

This “Respiratory syncytial virus (RSV) - Market Insights, Epidemiology, and Market Forecast - 2032” report delivers an in-depth understanding of the RSV, historical and forecasted epidemiology as well as the RSV market trends in the United States, EU4 (Germany, Spain, Italy, France) and the UK, and Japan.

The RSV market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted RSV market size from 2019 to 2032, segmented by seven major markets. The report also covers current RSV treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
  
• EU4 (Germany, France, Italy, Spain) and the UK
  
• Japan
  

Study Period: 2019-2032

Respiratory syncytial virus (RSV) Disease Understanding

This Respiratory syncytial virus (RSV) market report gives a thorough understanding of RSV by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

RSV is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. RSV belongs to the genus Orthopneumovirus within the family Pneumoviridae and order Mononegavirales. Members of this genus include human RSV, bovine RSV, and murine pneumonia virus. Two major antigenic subtypes of human RSV (A and B) are determined mainly by antigenic drift and duplications in RSV-G sequences but accompanied by genome-wide sequence divergence, including within RSV-F. Signs and symptoms of RSV infection most commonly appears about 4-6 days after exposure to the virus. RSV usually causes mild cold-like signs and symptoms in adults and older children. Signs and symptoms of severe RSV infection in infants include rapid breathing, cough, poor feeding, irritability, and unusual tiredness.

Diagnosis

Testing for RSV is often not needed. If it is required, several types of laboratory tests are used for diagnosis. The most commonly used is the rapid diagnostic test. This test looks for RSV antigens in nasal secretions. If the rapid test is negative, the doctor may order a virus culture of the secretions. The doctor may also choose a more sensitive test that uses genetic technology to detect the virus in the blood. Laboratory tests for RSV include rapid antigen detection tests (RADTs), direct fluorescent antibody (DFA), polymerase chain reaction (PCR), and viral cultures. Other tests include a blood test, chest x-rays, and pulse oximetry.

Treatment

Supportive care is the mainstay of treatment for RSV bronchiolitis. Most infants can be managed at home, but those who are ill-appearing, dehydrated, have poor feeding or apnea, develop respiratory distress or require supplemental oxygen should be considered for hospitalization. The typical length of stay in the hospital ranges 3-7 days. Supportive care includes hydration (i.e., oral or intravenous), clearing nasal obstruction with saline nose drops, nasal bulb suction or deep suctioning in the hospital, and nutrition for the patient. Bronchodilators, corticosteroids, antibiotics, and others are also used to treat RSV.

Respiratory syncytial virus (RSV) Epidemiology

The Respiratory syncytial virus (RSV) epidemiology section provides insights into the historical and current RSV patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.

Key Findings

• In 2022, the total incident cases of Respiratory syncytial virus (RSV) in the 7MM were ~8,495,000, and these cases are anticipated to increase during the study period.
  
• Total incident cases of RSV were highest in those below 5 years, followed by 65 years and above, and the least number of cases were found in the 5 to 64 years age group.
  
• The United States comprised ~58% of the total incident RSV cases in the 7MM in 2022.
  
• EU4, the UK, and Japan contributed ~30% and 12% to the total incident pool of RSV in 2022.
  
• In 2022, as per the severity of RSV infection in children, mild, moderate, and severe cases formed 70%, 27%, and 3% of the total incident cases of RSV in the US, respectively.
  
• The visit-specific distribution of RSV was further bifurcated into hospitalization and outpatient, making 7% and 93% of the treated cases of RSV in the US, respectively, in 2022.
  
• Due to the COVID-19 pandemic impact, a declining trend was observed in the RSV cases in 2020 across the 7MM countries. However, currently, the immunity gap developed due to the COVID-19 pandemic is proliferating the trend of RSV cases across the globe, leading to a sudden burden on healthcare systems.
  

The disease epidemiology covered in the report provides historical as well as forecasted Respiratory syncytial virus (RSV) epidemiology segmented as Total Incident Cases of RSV, Age-specific Incident Cases of RSV, Severity-specific Incident Cases of RSV in children, Severity-specific Incident Cases of Respiratory Syncytial Virus (RSV) in adults and Visit-specific Incident Cases of RSV in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) the United Kingdom, and Japan from 2019 to 2032.

Country-wise Respiratory syncytial virus (RSV) Epidemiology

This section provides a glimpse of the Respiratory syncytial virus (RSV) epidemiology in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

Respiratory syncytial virus (RSV) Drug Chapters

The drug chapter segment of the Respiratory syncytial virus (RSV) report encloses a detailed analysis of RSV-marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Respiratory syncytial virus (RSV) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Respiratory syncytial virus (RSV) marketed drugs

SYNAGIS (palivizumab): Swedish Orphan Biovitrum AB (SOBI):

Palivizumab is a humanized monoclonal antibody (IgG1?) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of RSV. SYNAGIS is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. In June 1998, SYNAGIS was approved to prevent serious lower respiratory tract disease caused by RSV in pediatric patients in the US.

Note: Detailed current therapies assessment will be provided in the full report of Respiratory syncytial virus (RSV)

Respiratory syncytial virus (RSV) emerging drugs

RSVpreF (PF-06928316): PfizerPfizer's investigational RSV vaccine candidate, RSVpreF, builds on foundational basic science discoveries, including those made at the National Institutes of Health (NIH), which detailed the crystal structure of prefusion F, a key form of the viral fusion protein (F) that RSV uses to attack human cells. In March 2022, Pfizer announced that its RSV vaccine candidate, PF-06928316 or RSVpreF, received BTD from the US FDA to prevent lower respiratory tract disease caused by RSV in individuals 60 years or older.

RSVPreF3 (GSK3844766A) Vaccine: GlaxoSmithKlineGSK3844766A contains a recombinant subunit pre-fusion RSV antigen combined with GSK's proprietary AS01 adjuvant, which is also used in the company's shingles vaccine. The drug has accepted regulatory submissions in Europe and Japan for older adults aged 60+. The Regulatory decision in the US is expected in the first half of 2023. US FDA has set a Prescription Drug User Fee Act action date of May 2023.

mRNA-1345: ModernaThe mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna's mRNA-1345 RSV vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response. In August 2021, Moderna received the FDA's FTD for the RSV vaccine (mRNA-1345) in adults older than 60.

Emerging Drug Insights

BEYFORTUS (nirsevimab), targeting the age segment of 0-1 years, bears an impressive efficacy, has a single dose schedule, was granted marketing authorization in the European Union in 2022, and is expected to launch this year in the US. The drug is expected to capture a significant market share considering half of the infants will receive the vaccine for RSV by its peak year. In the ‘older adult' age segment, GSK's vaccine RSVPreF3 outperforms Pfizer's vaccine. With the high vaccine efficacy demonstrated in this pivotal trial, GSK's vaccine candidate has the potential to help reduce the significant global burden of RSV-associated disease in older adults, including those at the greatest risk of severe outcomes due to their age or underlying comorbidities. It seems that Moderna's recent results may spoil the limelight from both GSK and Pfizer. On January 2023, Moderna announced results from the Phase III pivotal efficacy trial of mRNA-1345; the results were competitive with GSK and Pfizer's drug giving them tough competition.”

Note: Detailed emerging therapies assessment will be provided in the full report of Respiratory syncytial virus (RSV)

Respiratory syncytial virus (RSV) Market Outlook

While understanding Respiratory syncytial virus (RSV) pathogenesis and viral biology has increased over time, prevention of the virus is still lacking, often with severe disease burdens. Treatment for RSV infection is currently limited to supportive care and prophylactic antibody use. It may include hydration, supplemental oxygen, suctioning of airways, and mechanical ventilation when needed.

The FDA approves only two RSV antiviral drugs for treating or preventing serious respiratory tract infections caused by RSV: aerosolized ribavirin for treatment and palivizumab (SYNAGIS) for prophylaxis. Currently, multiple types of RSV vaccines are being pursued, specifically targeting populations of pregnant women, infants, and the elderly.

Based on the secondary sources and KOL insights for a prescription pattern of palivizumab in real-world settings, the usage of palivizumab in the US was around 20-25% whereas, in Europe and Japan, the utilization of palivizumab was comparatively less.

There is an unmet need for clinically effective, safe, cost-effective prevention and treatment options, including antiviral treatments, vaccines, and extended half-life mAbs. Challenges that must be encountered while generating safe and effective RSV vaccines or monoclonals include stringent safety measures in targeted pediatric and maternal populations. The development of novel RSV vaccines will hopefully help reduce the global burden caused by RSV. Until new interventions become available, optimizing the use of palivizumab in high-risk infants and children is important.

Key Findings

• The market size of the Respiratory syncytial virus (RSV) in the 7MM was observed to be ~USD 1,200 million in 2022.
  
• The United States constituted ~71% of the total RSV market share, followed by EU4 and the UK (23%), and Japan (6%).
  
• In 2022, palivizumab generated a revenue of around USD 400 million in the 7MM, and its revenue is expected to decrease over the years due to the upcoming therapies.
  
• GSK's RSVPreF3, Pfizer's RSVPreF, and Moderna's mRNA-1345 are expected to capture a significant market share in the upcoming years after launch. By the end of the forecast period, RSVPreF3, RSVPreF, and mRNA-1345 will capture 25%, 21%, and 9% of the total 7MM market, respectively.
  

The United States market outlook

This section provides the total Respiratory syncytial virus (RSV) market size and market size by therapies in the United States.

EU4 and the UK market outlook

This section provides the total Respiratory syncytial virus (RSV) market size and market size by therapies in EU4 and the UK.

Japan market outlook

This section provides the total Respiratory syncytial virus (RSV) market size and market size by therapies in Japan.

Respiratory syncytial virus (RSV) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Respiratory syncytial virus (RSV) market or expected to get launched in the market during the study period 2019-2032. The analysis covers RSV market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Respiratory syncytial virus (RSV) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and III. It also analyzes RSV key players in developing targeted therapeutics.

Pipeline development activities

The report covers collaborations, acquisitions, mergers, licensing, patent details, and other information for emerging RSV therapies.

Reimbursement Scenario in Respiratory syncytial virus (RSV)

Approaching reimbursement proactively can positively impact both during the late stages of product development and after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the Respiratory syncytial virus (RSV) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or RSV market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Respiratory syncytial virus (RSV) market using various competitive intelligence tools like SWOT analysis. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Respiratory syncytial virus (RSV), explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies.
  
• Comprehensive insight has been provided into the RSV epidemiology and treatment in the 7MM.
  
• Additionally, an all-inclusive account of the current and emerging therapies for RSV are provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  
• A detailed review of the RSV market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global RSV market.
  

Report Highlights

• In the coming years, the Respiratory syncytial virus (RSV) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, which would expand the market size to enable the drug manufacturers to penetrate more into the market.
  
• The companies and academics are working to assess challenges and seek opportunities that could influence RSV R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  
• Major players are involved in developing therapies for RSV. The launch of emerging therapies will significantly impact the RSV market.
  
• A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for RSV.
  
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
  

Respiratory syncytial virus (RSV) Report Insights

• Patient Population
  
• Therapeutic Approaches
  
• Respiratory syncytial virus (RSV) Pipeline Analysis
  
• Respiratory syncytial virus (RSV) Market Size and Trends
  
• Market Opportunities
  
• Impact of upcoming Therapies
  

Respiratory syncytial virus (RSV) Report Key Strengths

• 10 Years Forecast
  
• The 7MM Coverage
  
• Respiratory syncytial virus (RSV) Epidemiology Segmentation
  
• Key Cross Competition
  
• Highly Analyzed Market
  

Respiratory syncytial virus (RSV) Report Assessment

• Current Treatment Practices
  
• Unmet Needs
  
• Pipeline Product Profiles
  
• Market Attractiveness
  

Key Questions Answered

Market Insights:

• What was the Respiratory syncytial virus (RSV) drug class share (%) distribution in 2019 and what would it look like by 2032?
  
• What would be the RSV total market size and market size by therapies across the 7MM forecast period (2019-2032)?
  
• What are the key findings of the market across the 7MM, and which country will have the largest RSV market size during the forecast period (2019-2032)?
  
• At what CAGR is the RSV market expected to grow by 7MM during the forecast period (2019-2032)?
  
• What would be the RSV market outlook across the 7MM forecast period (2019-2032)?
  
• What would be the RSV market growth till 2032, and what will be the market size by 2032?
  
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
  

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Respiratory syncytial virus (RSV)?
  
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan?
  
• What is the historical RSV patient pool in seven major markets covering the United States, EU4 (Germany, France, Italy, Spain) and the UK and Japan?
  
• What would be the forecasted patient pool of RSV in seven major markets covering the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan?
  
• Where will be the growth opportunities in the 7MM concerning the patient population of RSV?
  
• Out of all the 7MM countries, which country would have the highest incident population of RSV during the forecast period (2019-2032)?
  
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
  

Epidemiology Insights:

• What are the current options for the Respiratory syncytial virus (RSV) treatment in addition to the approved therapies?
  
• What are the current treatment guidelines for treating RSV in the US, Europe, and Japan?
  
• What are the RSV-marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  
• How many companies are developing therapies for RSV?
  
• How many therapies are each company developing for RSV treatment?
  
• How many emerging therapies are in the mid-stage and late stage of development for RSV treatment?
  
• What are the key collaborations (Industry - Industry, Industry - Academia), mergers and acquisitions, and licensing activities related to the RSV therapies?
  
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
  
• What are the clinical studies for RSV and its status?
  
• What are the current challenges faced in drug development?
  
• What key designations have been granted for the emerging therapies for RSV?
  
• What are the global historical and forecasted markets of RSV?
  

Reasons to Buy

• The report will help develop business strategies by understanding trends shaping and driving the Respiratory syncytial virus (RSV) market.
  
• Organize sales and marketing efforts by identifying the best opportunities for RSV in the US, EU4 (Germany, France, Italy, Spain), and Japan.
  
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
  
• Organize sales and marketing efforts by identifying the best opportunities for the RSV market.
  
• To understand the future market competition in the RSV market.